Neogenomics Inc (NEO) 4.10 $NEO
NeoGenomics Schedules its Q4 2014 and Full Year 2014 Earnings Release for February 24, 2015
PR Newswire - Wed Feb 04, 5:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2014 and full year 2014 financial results on Tuesday February 24, 2015.
NEO: 4.10 (unch)
NeoGenomics ups Q4 guidance
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:15AM CST
NEO: 4.10 (unch)
NeoGenomics Raises Revenue Guidance to $25 Million and EPS Guidance to $0.01 - $0.02 per share for Quarter 4, 2014
PR Newswire - Thu Jan 22, 4:55PM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it was raising its previously issued revenue and earnings-per-share guidance for the fourth quarter of 2014. The Company now expects revenue of approximately $25 million and earnings per share of approximately $0.01 - $0.02 for the fourth quarter. Previously, the Company had issued revenue guidance of $23.0 - $24.5 million and earnings-per-share guidance of $0.00 - $0.01 per share.
NEO: 4.10 (unch)
NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program
PR Newswire - Tue Dec 16, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a research agreement with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) that will provide the basis to initiate a broad-spectrum translational program designed to expand the established clinical utility of comprehensive genomic profiling technologies in the development of oncology therapeutics from early pre-clinical studies to clinical practice.
NEO: 4.10 (unch)
United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 15.26 (-0.14), HH: 0.54 (+0.03), BRLI: 34.63 (+0.06), NEO: 4.10 (unch), DGX: 71.68 (+0.03), LH: 116.90 (+0.06), GHDX: 31.12 (+0.28)
United States Medical and Diagnostic Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6lcqc/medical_and) has announced the addition of Plunkett Research Ltd's new report "Medical and Diagnostic Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical and Diagnostic Laboratories Industry (U.S.) to reach $80.8 billion by 2021. - Medical and Diagnostic Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alliance Healthcare Services Inc - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - NeoGenomics Inc - Quest Diagnostics Inc - RadNet Inc For more information visit http://www.researchandmarkets.com/research/k6...edical_and Source: Plunkett Research Ltd
HH: 0.54 (+0.03), BRLI: 34.63 (+0.06), RDNT: 8.66 (-0.11), NEO: 4.10 (unch), DGX: 71.68 (+0.03), LH: 116.90 (+0.06), GHDX: 31.12 (+0.28)
N-of-One Selected by NeoGenomics to Provide Clinical Evidence for Interpreting Solid Tumor Next-Generation Sequencing Tests
Business Wire - Tue Dec 02, 7:31AM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services. Under this agreement, N-of-One will provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests being used by community pathologists and oncologists. Financial terms of the agreement are not disclosed.
NEO: 4.10 (unch)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 7.65 (+0.09), NEO: 4.10 (unch), AU: 12.33 (+0.36), FNHC: 29.64 (-0.29), AMS: 2.48 (+0.06), NYMX: 0.36 (-0.02), AMDA: 0.65 (+0.01), CVD: 107.08 (+0.05), GBIM: 7.85 (+0.25), RCAP: 10.28 (+0.28), KBIO: 0.45 (+0.06), COOL: 1.19 (unch), SAPE: 24.98 (-0.02), XTLB: 2.08 (-0.04), GERN: 3.03 (unch), ANIP: 62.69 (-0.43), BBLU: 1.26 (+0.09), NXTD: 2.70 (+0.04), AP: 18.27 (+0.09), ALQA: 6.14 (+0.09)
NeoGenomics' (NEO) CEO Doug VanOort on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:31AM CDT
NEO: 4.10 (unch)
Neogenomics raises full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 8:51AM CDT
NEO: 4.10 (unch)
Neogenomics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:26AM CDT
NEO: 4.10 (unch)
NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
PR Newswire - Thu Oct 30, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2014.
NEO: 4.10 (unch)
NeoGenomics to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, October 30, 2014
ACCESSWIRE - Wed Oct 29, 3:13PM CDT
FT. MYERS, FL / ACCESSWIRE / October 29, 2014 / NeoGenomics Inc. (NASDAQ:NEO) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, October 30, 2014 at 11:00 AM Eastern Time.
NEO: 4.10 (unch)
NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
PR Newswire - Thu Oct 23, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility to BTK inhibitors and test for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
NEO: 4.10 (unch)
NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
PR Newswire - Thu Oct 16, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the addition of a new comprehensive solid tumor profiling test designed for clinical discovery and to support clinical trials. The test utilizes next generation sequencing ("NGS"
to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization ("FISH" methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci.
NEO: 4.10 (unch)
NeoGenomics Appoints Robert J. Shovlin as Chief Operating Officer
PR Newswire - Mon Sep 29, 4:00PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the appointment of Robert Shovlin as Chief Operating Officer. This appointment will be effective as of Mr. Shovlin's expected start date of October 13, 2014.
NEO: 4.10 (unch)
NeoGenomics Schedules its Q3 2014 Earnings Release for October 30, 2014
PR Newswire - Wed Sep 24, 2:28PM CDT
NeoGenomics, Inc. (NASDAQ: NEO)announced today that it plans to release its third quarter 2014 financial results on Thursday October 30, 2014.
NEO: 4.10 (unch)
3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed Sep 10, 6:00AM CDT
Keep these stocks under $10 on your trading radar.
NEO: 4.10 (unch), DPRX: 12.76 (+0.26), GCAP: 8.67 (+0.17)
5 Under-$10 Stocks Making Big Moves Higher
at The Street - Fri Sep 05, 7:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
IRMD: 14.61 (-0.35), MY: 2.36 (unch), NEO: 4.10 (unch), LINC: 2.40 (+0.11), ARO: 3.63 (+0.04)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Thu Aug 28, 1:39PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
CAMT: 3.08 (+0.09), AGRX: 8.57 (-0.41), NEO: 4.10 (unch), CYTR: 2.96 (+0.23), ATRS: 2.45 (+0.05), TA: 13.30 (+0.08)
NeoGenomics Schedules its Q4 2014 and Full Year 2014 Earnings Release for February 24, 2015
PR Newswire - Wed Feb 04, 5:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2014 and full year 2014 financial results on Tuesday February 24, 2015.
NEO: 4.10 (unch)
NeoGenomics ups Q4 guidance
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:15AM CST
NEO: 4.10 (unch)
NeoGenomics Raises Revenue Guidance to $25 Million and EPS Guidance to $0.01 - $0.02 per share for Quarter 4, 2014
PR Newswire - Thu Jan 22, 4:55PM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it was raising its previously issued revenue and earnings-per-share guidance for the fourth quarter of 2014. The Company now expects revenue of approximately $25 million and earnings per share of approximately $0.01 - $0.02 for the fourth quarter. Previously, the Company had issued revenue guidance of $23.0 - $24.5 million and earnings-per-share guidance of $0.00 - $0.01 per share.
NEO: 4.10 (unch)
NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program
PR Newswire - Tue Dec 16, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a research agreement with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) that will provide the basis to initiate a broad-spectrum translational program designed to expand the established clinical utility of comprehensive genomic profiling technologies in the development of oncology therapeutics from early pre-clinical studies to clinical practice.
NEO: 4.10 (unch)
United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 15.26 (-0.14), HH: 0.54 (+0.03), BRLI: 34.63 (+0.06), NEO: 4.10 (unch), DGX: 71.68 (+0.03), LH: 116.90 (+0.06), GHDX: 31.12 (+0.28)
United States Medical and Diagnostic Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6lcqc/medical_and) has announced the addition of Plunkett Research Ltd's new report "Medical and Diagnostic Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical and Diagnostic Laboratories Industry (U.S.) to reach $80.8 billion by 2021. - Medical and Diagnostic Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alliance Healthcare Services Inc - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - NeoGenomics Inc - Quest Diagnostics Inc - RadNet Inc For more information visit http://www.researchandmarkets.com/research/k6...edical_and Source: Plunkett Research Ltd
HH: 0.54 (+0.03), BRLI: 34.63 (+0.06), RDNT: 8.66 (-0.11), NEO: 4.10 (unch), DGX: 71.68 (+0.03), LH: 116.90 (+0.06), GHDX: 31.12 (+0.28)
N-of-One Selected by NeoGenomics to Provide Clinical Evidence for Interpreting Solid Tumor Next-Generation Sequencing Tests
Business Wire - Tue Dec 02, 7:31AM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services. Under this agreement, N-of-One will provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests being used by community pathologists and oncologists. Financial terms of the agreement are not disclosed.
NEO: 4.10 (unch)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 7.65 (+0.09), NEO: 4.10 (unch), AU: 12.33 (+0.36), FNHC: 29.64 (-0.29), AMS: 2.48 (+0.06), NYMX: 0.36 (-0.02), AMDA: 0.65 (+0.01), CVD: 107.08 (+0.05), GBIM: 7.85 (+0.25), RCAP: 10.28 (+0.28), KBIO: 0.45 (+0.06), COOL: 1.19 (unch), SAPE: 24.98 (-0.02), XTLB: 2.08 (-0.04), GERN: 3.03 (unch), ANIP: 62.69 (-0.43), BBLU: 1.26 (+0.09), NXTD: 2.70 (+0.04), AP: 18.27 (+0.09), ALQA: 6.14 (+0.09)
NeoGenomics' (NEO) CEO Doug VanOort on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:31AM CDT
NEO: 4.10 (unch)
Neogenomics raises full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 8:51AM CDT
NEO: 4.10 (unch)
Neogenomics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:26AM CDT
NEO: 4.10 (unch)
NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
PR Newswire - Thu Oct 30, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2014.
NEO: 4.10 (unch)
NeoGenomics to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, October 30, 2014
ACCESSWIRE - Wed Oct 29, 3:13PM CDT
FT. MYERS, FL / ACCESSWIRE / October 29, 2014 / NeoGenomics Inc. (NASDAQ:NEO) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, October 30, 2014 at 11:00 AM Eastern Time.
NEO: 4.10 (unch)
NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
PR Newswire - Thu Oct 23, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility to BTK inhibitors and test for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
NEO: 4.10 (unch)
NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
PR Newswire - Thu Oct 16, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the addition of a new comprehensive solid tumor profiling test designed for clinical discovery and to support clinical trials. The test utilizes next generation sequencing ("NGS"
to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization ("FISH" methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci. NEO: 4.10 (unch)
NeoGenomics Appoints Robert J. Shovlin as Chief Operating Officer
PR Newswire - Mon Sep 29, 4:00PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the appointment of Robert Shovlin as Chief Operating Officer. This appointment will be effective as of Mr. Shovlin's expected start date of October 13, 2014.
NEO: 4.10 (unch)
NeoGenomics Schedules its Q3 2014 Earnings Release for October 30, 2014
PR Newswire - Wed Sep 24, 2:28PM CDT
NeoGenomics, Inc. (NASDAQ: NEO)announced today that it plans to release its third quarter 2014 financial results on Thursday October 30, 2014.
NEO: 4.10 (unch)
3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed Sep 10, 6:00AM CDT
Keep these stocks under $10 on your trading radar.
NEO: 4.10 (unch), DPRX: 12.76 (+0.26), GCAP: 8.67 (+0.17)
5 Under-$10 Stocks Making Big Moves Higher
at The Street - Fri Sep 05, 7:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
IRMD: 14.61 (-0.35), MY: 2.36 (unch), NEO: 4.10 (unch), LINC: 2.40 (+0.11), ARO: 3.63 (+0.04)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Thu Aug 28, 1:39PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
CAMT: 3.08 (+0.09), AGRX: 8.57 (-0.41), NEO: 4.10 (unch), CYTR: 2.96 (+0.23), ATRS: 2.45 (+0.05), TA: 13.30 (+0.08)
